UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Should You Buy?

Shares of UCB SA (OTCMKTS:UCBJF) saw unusually-high trading volume on Monday. Approximately 3,864 shares changed hands during trading, an increase of 493% from the average daily volume of 652 shares. The stock last traded at $313.8125 and had previously closed at $317.34.

Wall Street Analysts Forecast Growth

UCBJF has been the subject of several analyst reports. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Finally, Stephens reissued an “overweight” rating on shares of UCB in a research report on Wednesday, October 21st. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, UCB has a consensus rating of “Moderate Buy”.

UCB Price Performance

The company has a fifty day moving average of $256.20 and a two-hundred day moving average of $285.90. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).